These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25623322)

  • 1. [Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].
    Jiang Z; Yang Y; Pan Z; Yue Z; Li L
    Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(48):3854-8. PubMed ID: 25623322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
    Liao N; Zhang GC; Li XR; Yao M; Wang K
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
    Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
    Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
    Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
    Abramovitz M; Williams C; Loibl S; Leyland-Jones B
    Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis.
    Ma W; Zhao F; Zhou C; Zhang Y; Zhao Y; Li N; Xie P
    Onco Targets Ther; 2019; 12():379-390. PubMed ID: 30655674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
    Witzel I; Loibl S; von Minckwitz G; Eidtmann H; Fehm T; Khandan F; Schmatloch S; Hauschild M; Bischoff J; Fasching PA; Mau C; Schem C; Rack B; Meinhold-Heerlein I; Liedtke C; Karn T; Huober J; Zu Eulenburg C; Issa-Nummer Y; Untch M; Müller V
    Br J Cancer; 2012 Sep; 107(6):956-60. PubMed ID: 22892393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
    Guarneri V; Frassoldati A; Bottini A; Cagossi K; Bisagni G; Sarti S; Ravaioli A; Cavanna L; Giardina G; Musolino A; Untch M; Orlando L; Artioli F; Boni C; Generali DG; Serra P; Bagnalasta M; Marini L; Piacentini F; D'Amico R; Conte P
    J Clin Oncol; 2012 Jun; 30(16):1989-95. PubMed ID: 22493419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
    Vazquez JC; Antolin S; Ruiz-Borrego M; Servitja S; Alba E; Barnadas A; Lluch A; Martin M; Rodriguez-Lescure A; Sola I; Bonfill X; Urrutia G; Sanchez-Rovira P
    Clin Transl Oncol; 2023 Apr; 25(4):941-958. PubMed ID: 36417083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.